Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
Is there a PTH elevation above which you would be hesitant to use an anabolic agent in a patient with osteoporosis and CKD stage 4 or 5?
Related Questions
During treatment of severe osteoporosis, with PTH analogs (abaloparatide or) would rise in alkaline phosphatase level > 200 (in setting of normal GGT) warrant discontinuation of medication?
How do you approach significant change in BMD in premenopausal patient on tamoxifen?
Can raloxifene be combined with stronger osteoporosis agents in patients who are on raloxifene for a breast cancer diagnosis?
How do you use P1NP in your clinical practice to guide management of osteoporosis?
Have you been able to safely use other bisphosphonates in patients who developed an allergic reaction (angioedema) to fosamax?
Would you consider using Evenity in an elderly patient with rate controlled atrial fibrillation without history of MI or CVA?
How would you approach a finding of osteoporosis (Z score -4.5) in a recently postpartum patient who had DEXA sent for long-term low-dose glucocorticoid use?
When discontinuing Denosumab after more than 2-3 years of therapy, when do you recommend giving the first dose of zoledronic acid?
Would you consider teriparatide use in a patient with prior radiation therapy, given that the black box warning regarding osteosarcoma risk has been removed by the FDA?
Would you consider PTH analogue in a patient with mildly elevated PTH?
